[논문]Oseltamivir

Tullu, MS

doi:10.4103/0022-3859.57411

[해외논문] Oseltamivir 원문보기

Journal of postgraduate medicine, v.55 no.3, 2009년, pp.225 - 230

Tullu, MS

Abstract ▼ AI-Helper

Oseltamivir, a selective neuraminidase enzyme inhibitor, has gained worldwide attention in view of Influenza A (H1N1) pandemic. It is one of the most important drugs effective against the novel influenza virus. Oseltamivir is used for the treatment of uncomplicated acute illness due to influenza infection. Early initiation of treatment with the drug provides greater clinical benefits. The drug can also be effectively used for prophylaxis. Oseltamivir is readily absorbed from the gastrointestinal tract and is converted to the active metabolite- oseltamivir carboxylate, which has a wider distribution in the body. Oseltamivir carboxylate is eliminated in the urine with a half-life of 6-10 h. The drug is generally well-tolerated and does not have many clinically significant drug interactions. Nausea and vomiting are the commonest adverse effects associated with its use. The standard adult dose for treatment is 75 mg twice a day for five days and the dose for prophylaxis is 75 mg once daily for at least seven days following contact with an infected individual. The dose needs to be adjusted in patients with renal failure but no adjustments are required in patients with hepatic impairment. Although most of the influenza virus strains are sensitive to oseltamivir, development of drug resistance may limit the clinical utility of the drug in the future.

참고문헌 (66)

Drugs Bardsley-Elliot 58 851 1999 10.2165/00003495-199958050-00007 Oseltamivir

상세보기
Ann Pharmacother McNicholl 35 57 2001 10.1345/aph.10118 Neuraminidase inhibitors: Zanamivir and oseltamivir

상세보기
Drugs Shigeta 58 861 1999 10.2165/00003495-199958050-00009 Oseltamivir (Guest Commentaries)

상세보기
Antiviral Res Leneva 48 101 2000 10.1016/S0166-3542(00)00123-6 The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses

상세보기
PLoS One Hanshaoworakul 4 e6051 2009 10.1371/journal.pone.0006051 Severe human influenza infections in Thailand: Oseltamivir treatment and risk factors for fatal outcome

상세보기
Drugs Fleming 58 861 1999 10.2165/00003495-199958050-00008 Oseltamivir (Guest Commentaries)

상세보기
Lancet Nicholson 355 1845 2000 10.1016/S0140-6736(00)02288-1 Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial

상세보기
Antimircob Agents Chemother Mendel 42 640 1998 10.1128/AAC.42.3.640 Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection

상세보기
Expert Opin Drug Saf Schirmer 8 357 2009 10.1517/14740330902840519 Oseltamivir for treatment and prophylaxis of influenza infection

상세보기
Drug Metab Dispos Hill 30 13 2002 10.1124/dmd.30.1.13 The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies

상세보기
Expert Opin Pharmacother Doucette 2 1671 2001 10.1517/14656566.2.10.1671 Oseltamivir: A clinical and pharmacological perspective

상세보기
Clin Pharmacokinet He 37 471 1999 10.2165/00003088-199937060-00003 Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802

상세보기
Br J Clin Pharmacol Snell 59 598 2005 10.1111/j.1365-2125.2005.02340.x Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate

상세보기
J Clin Pharmacol Massarella 40 836 2000 10.1177/00912700022009567 The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers

상세보기
Eur J Clin Pharmacol Oo 59 411 2003 10.1007/s00228-003-0639-6 Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years

상세보기
Paediatr Drugs Oo 3 229 2001 10.2165/00128072-200103030-00005 Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children

상세보기
JAMA Treanor 283 1016 2000 10.1001/jama.283.8.1016 Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial

상세보기
BMJ Clin Evidence Jefferson 3 911 2009 Influenza
J Antimicrob Chemother Aoki 51 123 2003 10.1093/jac/dkg007 Early administration of oral oseltamivir increases the benefits of influenza treatment

상세보기
Lancet Infect Dis Burch 9 537 2009 10.1016/S1473-3099(09)70199-9 Prescription of anti-influenza drugs for healthy adults: A systematic review and meta-analysis

상세보기
Arch Intern Med Kaiser 163 1667 2003 10.1001/archinte.163.14.1667 Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations

상세보기
Curr Med Res Opin Lin 22 75 2006 10.1185/030079906X80297 A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population

상세보기
Ann Intern Med Rothberg 139 321 2003 10.7326/0003-4819-139-5_Part_1-200309020-00007 Management of influenza in adults older than 65 years of age: Cost-effectiveness of rapid testing and antiviral therapy

상세보기
JAMA Hayden 282 1240 1999 10.1001/jama.282.13.1240 Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment

상세보기
N Engl J Med Hayden 341 1336 1999 10.1056/NEJM199910283411802 Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

상세보기
BMJ Cooper 326 1235 2003 10.1136/bmj.326.7401.1235 Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: Systematic review and meta-analyses of randomised controlled trials

상세보기
JAMA Welliver 285 748 2001 10.1001/jama.285.6.748 Effectiveness of oseltamivir in preventing influenza in household contacts: A randomized controlled trial

상세보기
J Infect Dis Hayden 189 440 2004 10.1086/381128 Management of influenza in households: A prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis

상세보기
J Am Geriatr Soc Risebrough 53 444 2005 10.1111/j.1532-5415.2005.53162.x Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities

상세보기
J Am Geriatr Soc Peters 49 1025 2001 10.1046/j.1532-5415.2001.49204.x Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population

상세보기
Intern Med Shijubo 41 366 2002 10.2169/internalmedicine.41.366 Experience with oseltamivir in the control of nursing home influenza A outbreak

상세보기
Bone Marrow Transplant Machado 34 111 2004 10.1038/sj.bmt.1704534 Use of Oseltamivir to control influenza complications after bone marrow transplantation

상세보기
Pediatr Infect Dis J Whitley 20 127 2001 10.1097/00006454-200102000-00002 Oral oseltamivir treatment of influenza in children

상세보기
Pediatr Infect Dis J Johnston 24 225 2005 10.1097/01.inf.0000154322.38267.ce Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma

상세보기
Pediatrics Piedra 124 170 2009 10.1542/peds.2008-0977 Effects of oseltamivir on influenza-related complications in children with chronic medical conditions

상세보기
Euro Surveill Wallensten 14 19285 2009 10.2807/ese.14.30.19285-en Compliance and side effects of prophylactic oseltamivir treatment in a school in South West England

상세보기
Clin Infect Dis Sugaya 44 197 2007 10.1086/509925 Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children

상세보기
Pediatr Infect Dis J Huang 28 647 2009 10.1097/INF.0b013e3181986bf9 Influenza-associated central nervous system dysfunction in Taiwanese children: Clinical characteristics and outcomes with and without administration of oseltamivir

상세보기
Int J Clin Pract Smith 63 596 2009 10.1111/j.1742-1241.2009.02010.x Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment

상세보기
Euro Surveill Kitching 14 19287 2009 10.2807/ese.14.30.19287-en Oseltamivir adherence and side effects among children in three London schools affected by influenza A (H1N1)v, May 2009: An internet-based cross-sectional survey

상세보기
CMAJ Tanaka 181 55 2009 10.1503/cmaj.090866 Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women

상세보기
BMJ Stohr 326 1223 2003 10.1136/bmj.326.7401.1223 Preventing and treating influenza: Neuraminidase inhibitors are clinically effective but have limitations

상세보기
Immunopharmacology Burger 47 45 2000 10.1016/S0162-3109(99)00184-8 Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice

상세보기
N Engl J Med Moscona 353 2633 2005 10.1056/NEJMp058291 Oseltamivir resistance-disabling our influenza defenses

상세보기
N Engl J Med de Jong 353 2667 2005 10.1056/NEJMoa054512 Oseltamivir resistance during treatment of influenza A (H5N1) infection

상세보기
PLoS Med White 6 e1000091 2009 10.1371/journal.pmed.1000091 What is the optimal therapy for patients with H5N1 influenza?

상세보기
J Antimicrob Chemother Ward 55 i5 2005 10.1093/jac/dki018 Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic

상세보기
Proc Natl Acad Sci USA Tumpey 99 13849 2002 10.1073/pnas.212519699 Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus

상세보기
Nature Le 437 1108 2005 10.1038/4371108a Avian flu: Isolation of drug-resistant H5N1 virus

상세보기
Antivir Ther Aoki 12 603 2007 10.1177/135965350701200S04.1 Influenza virus susceptibility and resistance to oseltamivir

상세보기
JAMA Gooskens 301 1042 2009 10.1001/jama.2009.297 Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A (H1N1) virus

상세보기
Antimicrob Agents Chemother McKimm-Breschkin 47 2264 2003 10.1128/AAC.47.7.2264-2272.2003 Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir

상세보기
Science Enserink 323 1162 2009 10.1126/science.323.5918.1162 Newsfocus: A ′wimpy′ flu strain mysteriously turns scary

상세보기
PLoS One Soderstrom 4 e6064 2009 10.1371/journal.pone.0006064 Detection of the antiviral drug oseltamivir in aquatic environments

상세보기
PLoS Med Shay 6 e1000103 2009 10.1371/journal.pmed.1000103 Can we ′′hedge′′ against the development of antiviral resistance among pandemic influenza viruses?

상세보기
Clin Infect Dis Poland 48 1254 2009 10.1086/598989 Influenza virus resistance to antiviral agents: A plea for rational use

상세보기
Clin Infect Dis Stephenson 48 389 2009 10.1086/596311 Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children

상세보기
Eur Surveill Hall 14 19282 2009 10.2807/ese.14.30.19282-en Pandemic influenza A(H1N1)v viruses currently circulating in New Zealand are sensitive to oseltamivir

상세보기
Emerg Infect Dis Besselaar 14 1809 2008 10.3201/eid1411.080958 Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa

상세보기
Emerg Infect Dis Cheng 15 966 2009 10.3201/eid1506.081357 Oseltamivir and amantadine-resistant influenza viruses A (H1N1)

상세보기
JAMA Dharan 301 1034 2009 10.1001/jama.2009.294 Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States

상세보기
Emerg Infect Dis Hauge 15 155 2009 10.3201/eid1502.081031 Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08

상세보기
Jpn J Infect Dis Kawakami 62 83 2009 10.7883/yoken.JJID.2009.83 Isolation of Oseltamivir-resistant influenza A/ H1N1 virus of different origins in Yokohama city, Japan, during the 2007-2008 influenza season

상세보기
Emerg Infect Dis Meijer 15 552 2009 10.3201/eid1504.181280 Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season

상세보기
N Engl J Med Moscona 360 953 2009 10.1056/NEJMp0900648 Global transmission of oseltamivir-resistant influenza

상세보기
JAMA Weinstock 301 1066 2009 10.1001/jama.2009.324 The evolution of influenza resistance and treatment

상세보기

활용도 분석정보

상세보기

다운로드

내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증